Pharmacy in Fremont, CA
Quark Pharmaceuticals. Is a clinical-stage pharmaceutical firm that is a leader in the discovery and development of novel RNAi-based therapeutics. QPI-1002 is the 1st synthetic siRNA to be evaluated following systemic administration in human clinical trials, and is tailored to temporarily inhibit expression of the stress-response gene, p53. QPI-1002 is being studied under two INDs for two indications - the prevention of acute kidney injury (AKI) in patients undergoing major cardiovascular surgery, and the prophylaxis of delayed graft function (DGF) in renal transplant patients.